RNA interference-directed silencing of VPAC 1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells

Molecular and Cellular Endocrinology

Volumn 348, Issue 1, 2012, Pages 241-246

  Valdehita, Ana ^a   Carmena, María J ^a   Bajo, Ana M ^a   Prieto, Juan C ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Angiogenesis; Breast cancer; HER transactivation; VEGF; VIP

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 5 (2 BENZOTHIAZOLYL)THIOMETHYL 4 HYDROXY 3 METHOXYBENZYLIDENECYANOACETAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN TYROSINE KINASE; VASCULOTROPIN; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN SECRETION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; RNA INTERFERENCE; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASOACTIVE INTESTINAL PEPTIDE;

EID: 80755138420     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.08.031     Document Type: Article

References (48)

1. Anido J., Matar P., Albanell J., Guzmán M., Rojo F., Arribas J., Averbuch S., Baselga J. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin in HER2-overexpressing breast cancer cells. Clin. Cancer Res. 2003, 9:1274-1283.
2. Atalay G., Cardoso F., Awada A., Piccart M.J. Novel therapeutic strategies targeting the epidermal growth factor (EGFR) family and its downstream effectors in breast cancer. Ann. Oncol. 2003, 14:1346-1363.
3. Bachelder R.E., Crago A., Chung J., Wendt M.A., Shaw L.M., Robinson G., Mercurio A.M. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res. 2001, 61:5736-5740.
4. Barros F.F., Powe D.G., Ellis I.O., Green A.R. Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. Histopathology 2010, 56:560-572.
5. Bellyei S., Schally A.V., Zarandi M., Varga J.L., Vidaurre I., Pozsgai E. GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro. Cancer Lett. 2010, 293:31-40.
6. Bhola N.E., Grandis J.R. Crosstalk between G-protein coupled receptors and epidermal growth factor receptor in cancer. Front. Biosci. 2008, 13:1857-1865.
7. Biscardi J.S., Ishizawa R.C., Silva C.M., Parsons S.J. Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res. 2000, 2:203-210.
8. Bombonati A., Sgroi D.C. The molecular pathology of breast cancer progression. J. Pathol. 2011, 223:307-317.
9. Boudreau N., Myers C. Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment. Breast Cancer Res. 2003, 5:140-146.
10. Casanueva F.F., Camiña J.P., Carreira M.C., Pazos Y., Varga J.L., Schally A.V. Growth hormone-releasing hormone as an agonist of the ghrelin receptor GHS-R1a. Proc. Natl Acad. Sci. USA 2008, 105:20452-20457.
11. Chorny A., González-Rey E., Varela N., Robledo G., Delgado M. Signalling mechanisms of vasoactive intestinal peptide in inflammatory conditions. Regul. Pept. 2006, 137:67-74.
12. Chowdhury E.H. Strategies for tumor-directed delivery of siRNA. Expert Opin. Drug Delivery 2011, 8:389-401.
13. 1 receptor binding site: contribution of photoaffinity labeling approach. Neuropeptides 2010, 44:127-132.
14. De Castro G., Puglisi F., De Azambuja E., El Saghir N.S., Awada A. Angiogenesis and cancer: a cross-talk between basic science and clinical trials (the " do ut des" paradigm). Crit. Rev. Oncol. Hematol. 2006, 59:40-50.
15. Dickson L., Finlayson K. VPAC and PAC receptors: from ligands to function. Pharmacol. Ther. 2009, 121:294-316.
16. Donovan E.A., Kummar S. Targeting VEGF in cancer therapy. Curr. Probl. Cancer 2006, 30:7-32.
17. Fahrenkrug J., Said S.I. VIP, PACAP, glucagons, and related peptides. Ann. N. Y. Acad. Sci. 2000, 921:1-110.
18. Fernández-Martínez A.B., Bajo A.M., Arenas M.I., Sánchez-Chapado M., Prieto J.C., Carmena M.J. Vasoactive intestinal peptide (VIP) induces malignant transformation on the human prostate epithelial cell line RWPE-1. Cancer Lett. 2010, 299:11-21.
19. García-Fernández O., Collado B., Bodega G., Cortés J., Ruíz-Villaespesa A., Carmena M.J., Prieto J.C. Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue. Gynecol. Endocrinol. 2005, 20:327-333.
20. Higashiyama S., Iwabuki H., Morimoto C., Hieda M., Inove H., Matsushita N. Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands. Cancer Sci. 2008, 99:214-220.
21. Holmes K., Roberts O.L., Thomas A.M., Cross M.J. Vascular endothelial growth factor receptor-2: structure, function, intracellular signaling and therapeutic inhibition. Cell. Signal. 2007, 19:2003-2012.
22. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. Cancer J. Clin. 2010, 60:277-300.
23. Kóvacs M., Schally A.V., Varga J.L., Zarándi M. Endocrine and antineoplastic actions of growth hormone-releasing hormone antagonists. Curr. Med. Chem. 2008, 15:314-321.
24. Kushlinskii N.E., Gershtein R.S. Role of vascular endothelial growth factor during breast cancer. Bull. Exp. Biol. Med. 2002, 133:521-528.
25. Laburthe M., Couvineau A. Molecular pharmacology and structure of PACAP receptors for VIP and PACAP. Regul. Pept. 2002, 108:165-173.
26. Laburthe M., Couvineau A., Tan V. Class II G-protein coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides 2007, 28:1631-1639.
27. Lin N.U., Winer E.P. New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. Breast Cancer Res. 2004, 6:204-210.
28. Lin S.X., Chen J., Mazumdar M., Poirier D., Wang C., Azzi A., Zhou M. Molecular therapy of breast cancer: progress and future directions. Nat. Rev. Endocrinol. 2010, 6:485-493.
29. Linderholm B., Grankvist K., Wilking N., Johansson M., Travelin B., Henriksson R. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J. Clin. Oncol. 2000, 18:1423-1431.
30. Linderholm B., Tavelin B., Grankvist K., Henriksson R. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J. Clin. Oncol. 1998, 16:3121-3128.
31. Lochmatter D., Mullis P.E. RNA interference in mammalian cell systems. Horm. Res. Paediatr. 2011, 75:63-69.
32. Mass R.D. The HER receptor family: a rich target for therapeutic development. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58:932-940.
33. Moody T.W., Gozes I. Vasoactive intestinal peptide receptors: a molecular target in breast and lung cancer. Curr. Pharm. Des. 2007, 13:1099-1104.
34. Moody T.W., Hill J.M., Jensen R.T. VIP as a trophic factor in the CNS and cancer cells. Peptides 2003, 24:163-177.
35. Moody T.W., Ito T., Osefo N., Jensen R.T. VIP and PACAP recent insights into their functions/roles in physiology and disease from molecular and genetic studies. Curr. Opin. Endocrinol. Diabetes Obes. 2011, 18:61-67.
36. 1 receptors. Ann. N. Y. Acad. Sci. 2006, 1070:436-439.
37. Ongusaha P.P., Kwak J.C., Zwible A.J., Macip S., Higashiyama S., Taniguchi N., Fang L., Lee S.W. HB-EGF is a potent inducer of tumor-growth and angiogenesis. Cancer Res. 2004, 64:5283-5290.
38. Pidgeon G.P., Barr M.P., Harmey J.H., Foley D.A., Bouchier-Hayes D.J. Vascular endothelial growth factor (VEGF) upregulates Bcl-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br. J. Cancer 2001, 85:273-278.
39. Plonowski A., Varga J.L., Schally A.V., Krupa M., Groot K., Halmos G. Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity. Int. J. Cancer 2002, 98:624-629.
40. Popat S., Smith I.E. Breast cancer. Update Cancer Ther. 2006, 1:187-210.
41. Roskoski Jr.J. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit. Rev. Oncol. Hematol. 2007, 62:179-213.
42. Ross J.S., Slodkowska E.A., Symmans W.F., Pusztai L., Ravdin P.M., Hortobagyi G.N. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009, 14:320-368.
43. Schally A.V., Varga J.L., Engel J.B. Antagonists of growth-hormone releasing hormone: an emerging new therapy for cancer. Nat. Clin. Pract. Endocrinol. Metab. 2008, 4:33-43.
44. Sebastian S., Settleman J., Reshkin S.J., Azzariri A., Bellizi A., Paradiso A. The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim. Biophys. Acta 2006, 1766:120-139.
45. Singer C.F., Köstler W.J., Hudelist G. Predicting the efficiency of trastuzumab-based therapy in breast cancer: current standards and future strategies. Biochim. Biophys. Acta 2008, 1786:105-113.
46. Valdehita A., Bajo A.M., Schally A.V., Varga J.L., Carmena M.J., Prieto J.C. Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells. Mol. Cell. Endocrinol. 2009, 302:341-348.
47. Valdehita A., Carmena M.J., Collado B., Prieto J.C., Bajo A. Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells. Regul. Pept. 2007, 144:101-108.
48. Weigel B., Baehner F.L., Reis-Filho J.S. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J. Pathol. 2010, 220:263-280.